(MedPage Today) — SAN FRANCISCO — An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended treatment benefit versus transarterial chemoembolization (TACE), according to an interim analysis…
Source link : https://www.medpagetoday.com/meetingcoverage/mgics/119373
Author :
Publish date : 2026-01-10 20:15:00
Copyright for syndicated content belongs to the linked Source.
